Form 4: Centessa CMO Granted 120,000 RSUs in Equity Award

Centessa Pharmaceuticals plc's Chief Medical Officer, Stephen Kanes, was granted 120,000 Restricted Share Units vesting over four years.

Summary

• Stephen Kanes, Chief Medical Officer of Centessa Pharmaceuticals plc, was granted 120,000 Ordinary Shares in the form of Restricted Share Units (RSUs).
• The grant occurred on February 2, 2026, with a transaction price of $0 per share, indicating an equity award.
• These RSUs are issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan.
• The RSUs will vest in four equal annual installments, with the first vesting date on February 2, 2027.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• A substitute Power of Attorney was filed, appointing Raphael Deferiere as attorney-in-fact for Stephen Kanes and other executives for SEC filings, effective August 11, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for corporate governance and executive alignment, as it ties a key executive's compensation directly to the company's long-term performance through a standard equity grant.

Positives

• The grant of 120,000 Restricted Share Units to the Chief Medical Officer aligns management incentives with long-term shareholder value.
• The use of a Rule 10b5-1(c) plan indicates a pre-planned and structured approach to equity compensation, promoting transparency.

Negatives

• No immediate cash value for the recipient as RSUs vest over time, contingent on continued employment and company performance.

Risks

• Future share price performance could impact the ultimate value of the RSUs, introducing market risk for the compensation.
• Continued employment is required for vesting, posing a retention risk if the officer departs before full vesting.

Future Outlook

The filing details a future equity grant and its vesting schedule, indicating a long-term incentive for the Chief Medical Officer. The first vesting is scheduled for February 2, 2027, with subsequent annual vestings over four years.

Management Comments

• The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• The shares reported in this transaction represent Restricted Share Units ('RSUs') issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan.
• Each RSU represents the contingent right to receive one Ordinary Share of the Issuer.
• The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through Restricted Share Units, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This grant aligns Stephen Kanes' interests with the company's long-term performance, a common strategy in a sector with lengthy development cycles and high R&D costs.

Comparison to Industry Standards

• The grant of 120,000 RSUs to a Chief Medical Officer is a significant equity award, comparable to incentive packages seen at similar-stage biotech companies.
• A four-year vesting schedule with annual installments is a common industry standard for executive equity compensation, aiming to promote long-term retention and performance.
• The use of a 10b5-1 plan for such grants is also standard practice, providing a legal framework for insider transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased long-term value if the RSU grant incentivizes the Chief Medical Officer to drive company performance. Dilution risk upon vesting, though this is standard for equity compensation plans.
• Employees: May signal stability and a commitment to executive retention, potentially boosting morale within the company.

Next Steps

• Stephen Kanes' RSUs will begin vesting on February 2, 2027, with subsequent annual vestings over the following three years.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key executive, which is an expected part of corporate governance and incentive structures. It does not present new information that would fundamentally alter the investment thesis for Centessa Pharmaceuticals plc, thus a 'hold' recommendation is appropriate as it maintains the existing outlook without providing a strong catalyst for 'buy' or 'sell'.

Keywords

Centessa Pharmaceuticals, CNTA, Stephen Kanes, Restricted Share Units, RSU, Equity Compensation, Insider Transaction, Form 4, Biotechnology, Pharmaceuticals